TECHNOLOGY
Two transcranial direct current stimulation (tDCS) devices. Same price. Both advertise 2 mA. Both name the prefrontal cortex. Both show a person looking calm in good lighting.
Loading…
Continue Reading
Related articles from the knowledge base
THE MECHANISM
What Is tDCS? Transcranial Direct Current Stimulation Guide (2026)
10 min read
THE SCIENCE
We Reviewed 25 Peer-Reviewed Studies So You Don't Have To. Here's What the Science Actually Says About tDCS.
15 min read
REGULATORY
Is Sychedelic FDA Approved? What CDSCO and IEC 60601-1-2 Actually Mean
12 min read
TECHNOLOGY
What Is Closed-Loop tDCS, and Why It Changes Everything
12 min read
FREQUENTLY ASKED
No, and the differences that matter are mostly invisible on a spec sheet. Two devices can both deliver 2 mA to the prefrontal cortex while differing in whether current holds steady when scalp resistance changes, whether the session ends on a hardware timer or an app instruction, whether contact quality is checked at all, and whether placement is reproducible between sessions. Those four differences change the delivered dose. The advertised current tells you about none of them.
Constant-current output with a hardware-enforced ceiling, a fully published dose including electrode positions and areas, impedance checking before and during the session, a mechanism that reproduces placement every time, hardware-enforced session limits, and honest disclosure of both regulatory status and evidence. Everything else is refinement on top of those six.
Better at different jobs. Wearable and integrated designs generally win on placement repeatability, since fixed geometry removes the main source of session-to-session variation, and on adherence, since the device is part of an existing habit. Traditional strap-and-stimulator setups win on montage flexibility. Given that the strongest evidence comes from multi-session protocols and that positioning error meaningfully changes current flow, repeatability matters more than flexibility for most consumer buyers.
More than marketing admits, and in a way most devices cannot address. Response varies widely between individuals, with motor cortex studies finding only around 36% to 50% of participants responding in the expected direction. Much of that comes from fixed anatomy: skull thickness, cerebrospinal fluid volume and scalp-to-cortex distance all affect how much current reaches the target, and no consumer device measures any of them. What some devices can personalise is timing, by measuring autonomic state and adjusting when stimulation happens. That is real and defensible. It is not the same as personalising dose to your anatomy, and a brand blurring the two is overstating its hardware.
Within conventional parameters, the published record is reassuring: no serious adverse events across more than 33,200 sessions in over 1,000 subjects at 4 mA or less and 40 minutes or less. Two qualifications matter. That record comes from screened populations, and long-term data for extended unsupervised use remains limited. Standard exclusions include metal implants in or near the head, cardiac pacemakers or implanted defibrillators, personal or family history of epilepsy or unprovoked seizures, active skin conditions at the electrode sites, pregnancy, and medications lowering the seizure threshold. Mild tingling and transient scalp redness are expected. Persistent headache, visual disturbances, skin blistering, and unusual mood changes are not, and warrant stopping and speaking to a doctor.
It depends entirely on what the price buys. Constant-current circuitry, hardware ceilings and timers, impedance monitoring and reproducible placement all cost money to engineer and matter most for unsupervised home use. Industrial design, app polish and session variety also cost money and matter far less. Price alone tells you nothing. Work out which side of that split the money went to.
For consumer wellness devices, no. They are sold directly without prescription, which also means no regulator has independently assessed their benefit claims. The one FDA-approved tDCS device, indicated for moderate-to-severe major depressive disorder, is prescription-only, precisely because it is regulated as a treatment for a diagnosed condition.
Longer than most marketing implies, and honestly, it may not. Single-session effects in rested healthy adults are the most-cited null finding in the field. The reliable effects come from repeated sessions paired with cognitive work, which is why multi-session protocols exist at all. Any product promising a noticeable change on day one is describing something the evidence does not support.
THE INSTRUMENT
Sychedelic combines everything described in this article into one 20-minute protocol.